title: P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells.
abstract: Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. We previously demonstrated that cys-LTs cross-desensitized IL-4-primed primary human mast cells (hMCs) to stimulation with the nucleotide uridine diphosphate (UDP). We now report that hMCs, mouse bone marrow-derived mast cells (mBMMCs), and the human MC line LAD2 all express UDP-selective P2Y6 receptors that cooperate with CysLT1R to promote cell survival and chemokine generation by a pathway involving reciprocal ligand-mediated cross-talk. Leukotriene (LT) D4, the most potent CysLT1R ligand, and UDP both induced phosphorylation of ERK and prolonged the survival of cytokine-starved hMCs and mBMMCs. ERK activation and cytoprotection in response to either ligand were attenuated by treatment of the cells with a selective P2Y6 receptor antagonist (MRS2578), which did not interfere with signaling through recombinant CysLT1R. Surprisingly, both UDP and LTD4-mediated ERK activation and cytoprotection were absent in mBMMCs lacking CysLT1R and the biosynthetic enzyme LTC4 synthase, implying a requirement for a cys-LT-mediated autocrine loop. In IL-4-primed LAD2 cells, LTD4 induced the generation of MIP-1beta, a response blocked by short hairpin RNA-mediated knockdown of CysLT1R or P2Y6 receptors, but not of CysLT2R. Thus, CysLT1R and P2Y6 receptors, which are coexpressed on many cell types of innate immunity, reciprocally amplify one another's function in mast cells through endogenous ligands.
authors.affiliation: Department of Medicine, Harvard Medical School and Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Jiang
authors.forename: Laura
authors.initials: L
authors.lastname: Borrelli
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Bacskai
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Kanaoka
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Boyce
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002470:Cell Survival / Q000276:immunology; D002478:Cells, Cultured; D018925:Chemokines / Q000096:biosynthesis; D003545:Cysteine / Q000138:chemical synthesis* / Q000502:physiology*; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D015289:Leukotrienes / Q000138:chemical synthesis* / Q000502:physiology*; D008024:Ligands; D008407:Mast Cells / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D020239:Receptor Cross-Talk / Q000276:immunology; D018077:Receptors, Leukotriene / Q000502:physiology; D018048:Receptors, Purinergic P2 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology*; D014530:Uridine Diphosphate / Q000502:physiology
chemical_list: D018925:Chemokines; D015289:Leukotrienes; D008024:Ligands; D018077:Receptors, Leukotriene; D018048:Receptors, Purinergic P2; C112381:cysteinyl-leukotriene; C099845:purinoceptor P2Y6; D014530:Uridine Diphosphate; D003545:Cysteine; C083169:leukotriene D4 receptor